Search

647 Result(s)
Sort by

Nurjanahs Story

Nurjanahs Story

Nurjanah went from a sporty young woman to someone who no longer had the energy to do simple, everyday tasks. She was diagnosed with scleroderma.
Making sustainable medicines through eco-design

Making sustainable medicines through eco-design

Our goal is to minimize the environmental footprint of our medicines through integration of eco-design and green chemistry across the entire lifecycle
Fast-Track-Designation-NASH

Fast-Track-Designation-NASH

Boehringer Ingelheim and Zealand Pharma announced that the FDA granted Fast Track Designation to the dual agonist BI 456906 for adults with NASH.
BI_PharmAccess_launch_digital_healthcare_program

BI_PharmAccess_launch_digital_healthcare_program

Boehringer Ingelheim and PharmAccess launch a new mobile support program „Tiba Yako“ to empower patients to become more aware, access care and take charge of their disease management
Performance Indicators

Performance Indicators

Performance indicators concerning Environment Health and Safety (EHS) are summarized here.
Rafał Rybicki

Rafał Rybicki

Rafał Rybicki, Head of Legal and Compliance Services in our Global Business Service (GBS) Center in Wroclaw, looks back on a bustling beginning with Boehringer Ingelheim – for him and the Center alike.
Early careers

Early careers

At Boehringer Ingelheim, we know how important it is to lay the right foundations in your career and build on them with care and support.
Schizophrenia in real life

Schizophrenia in real life

Discover the reality of life with schizophrenia through the stories of people who are breaking down the stigma of living with a serious mental illness.
empulse-trial-benefit-acute-heart-failure

empulse-trial-benefit-acute-heart-failure

Empagliflozin provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE Phase III trial